Our data are in accordance with those published by other groups [8, 13, 14, 17, 22, 29, 37–41] and showed that FLT3-ITD mutation has a strong prognostic factor in AML patients and associated disease progression with high rate of relapse and shorter overall survival; median overall survival was 10.0 months for FLT3-mutated patients and 20.0 months for WT patients (P = 0.031), and event-free survival (EFS) was also worse for FLT3-positive patients than FLT3-WT patients (P = 0.040) because of a higher relapse rate. Here, FLT3 is linked to acute myeloid leukemia.